Andrew Phillips
Director/Board Member at ENLIVEN THERAPEUTICS, INC.
Net worth: - $ as of 2024-05-30
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Samuel Kintz | M | 38 |
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | 5 years |
Joseph Lyssikatos | M | 59 |
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | 5 years |
Anthony D. Piscopio | M | - |
OnKure, Inc.
OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO. | 13 years |
Mallory Morales | F | 40 | 3 years | |
Anish Patel | M | 43 |
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | 5 years |
R. Carruthers | M | 66 |
OnKure, Inc.
OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO. | 5 years |
Xuedong Liu | M | - |
OnKure, Inc.
OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO. | 13 years |
Anthony Killarney | M | - |
ONK Therapeutics Ltd.
ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | 9 years |
Frank G. Haluska | M | 64 |
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Kestrel Therapeutics, Inc. is a company that has two habitat restoration projects aimed at helping native animals that are at risk, specifically the American Kestrel and the Eastern Spadefoot Toad. The company is based in Wayland, MA. The company's mission is to conserve and care for forests, farms, and riverways of the Pioneer Valley while nurturing an enduring love of the land. The CEO of the company is Frank G. Haluska. | - |
Michael O'Dwyer | M | - |
ONK Therapeutics Ltd.
ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | 9 years |
Matthew D. Disney | M | - |
Expansion Therapeutics, Inc.
Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA. | - |
Catherine Moukheibir | F | 64 |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 2 years |
Daniel Timms | M | - |
BiVACOR, Inc.
BiVACOR, Inc. Medical SpecialtiesHealth Technology BiVACOR, Inc. develops and manufactures medical device. The firm specializes in rotary blood pumps, biomedical engineering. The company was founded by Daniel Timms in 2008 and is headquartered in Houston, TX. | 16 years |
Spike N. Loy | M | 43 |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 3 years |
Andrew Hirsch | M | 53 | 4 years | |
Ramnik Xavier | M | 62 |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 2 years |
Jake Bauer | M | 45 |
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | 2 years |
Richard Heyman | M | 66 |
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | 2 years |
Simon Sturge | M | 65 |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 3 years |
Jorge da Silva | M | 47 | 2 years | |
Mika Derynck | M | 61 |
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | 2 years |
Renato T. Skerlj | M | - |
Expansion Therapeutics, Inc.
Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA. | 4 years |
Kara Lassen | M | 45 |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 2 years |
Rishi Gupta | M | 46 |
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | 1 years |
Raymond Kelleher | M | 59 |
Expansion Therapeutics, Inc.
Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA.
BiVACOR, Inc.
BiVACOR, Inc. Medical SpecialtiesHealth Technology BiVACOR, Inc. develops and manufactures medical device. The firm specializes in rotary blood pumps, biomedical engineering. The company was founded by Daniel Timms in 2008 and is headquartered in Houston, TX.
ONK Therapeutics Ltd.
ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | 2 years |
Scott Rocklage | M | 69 |
Expansion Therapeutics, Inc.
Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA. | - |
Hugh O'Dowd | M | 59 |
ONK Therapeutics Ltd.
ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | 3 years |
Kristian Reich | M | 58 | 2 years | |
Michael Bookman | M | 37 | 3 years | |
Matthias Bodenstedt | M | 36 | 2 years | |
Oliver Daltrop | M | 47 |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 3 years |
Arnout Ploos van Amstel | M | 60 |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 3 years |
Rhamy Zeid | M | - |
Nexo Therapeutics, Inc.
Nexo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nexo Therapeutics is a small molecule oncology company that focuses on discovering and developing new drugs for cancer patients who do not have effective treatments. The company is based in Littleton, CO and Watertown, MA. The company uses covalent ligand discovery, chemical biology, cancer biology, and medicinal chemistry to target the underlying causes of cancer through innovative methods. Nexo Therapeutics was founded by John Athanosopoulos, Andrew J. Phillips, Michael Kim, and Rhamy Zeid. Andrew J. Phillips has been the CEO of the company since 2022. | - |
Laurie Keating | F | 70 | 3 years | |
Michael Kim | M | - |
Nexo Therapeutics, Inc.
Nexo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nexo Therapeutics is a small molecule oncology company that focuses on discovering and developing new drugs for cancer patients who do not have effective treatments. The company is based in Littleton, CO and Watertown, MA. The company uses covalent ligand discovery, chemical biology, cancer biology, and medicinal chemistry to target the underlying causes of cancer through innovative methods. Nexo Therapeutics was founded by John Athanosopoulos, Andrew J. Phillips, Michael Kim, and Rhamy Zeid. Andrew J. Phillips has been the CEO of the company since 2022. | - |
Jolie Siegel | F | 48 | 4 years | |
Jim Dillon | M | - |
BiVACOR, Inc.
BiVACOR, Inc. Medical SpecialtiesHealth Technology BiVACOR, Inc. develops and manufactures medical device. The firm specializes in rotary blood pumps, biomedical engineering. The company was founded by Daniel Timms in 2008 and is headquartered in Houston, TX. | - |
William Cohn | M | 64 |
BiVACOR, Inc.
BiVACOR, Inc. Medical SpecialtiesHealth Technology BiVACOR, Inc. develops and manufactures medical device. The firm specializes in rotary blood pumps, biomedical engineering. The company was founded by Daniel Timms in 2008 and is headquartered in Houston, TX. | 12 years |
Christopher Nowers | M | - |
ONK Therapeutics Ltd.
ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | 4 years |
Ann Berman | F | 71 | 3 years | |
Gary Bridger | M | 61 |
Expansion Therapeutics, Inc.
Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA. | 2 years |
Allan Reine | M | 49 |
ONK Therapeutics Ltd.
ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | 2 years |
George Hank Brown | M | 84 |
The University of Colorado
| 19 years |
Nicholas A. Saccomano | M | 65 |
OnKure, Inc.
OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO. | - |
Lauren Zucker | F | 54 |
Yale University
| 13 years |
Benjamin Hohl | M | 35 | 1 years | |
Andrew Phillips | M | - |
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Kestrel Therapeutics, Inc. is a company that has two habitat restoration projects aimed at helping native animals that are at risk, specifically the American Kestrel and the Eastern Spadefoot Toad. The company is based in Wayland, MA. The company's mission is to conserve and care for forests, farms, and riverways of the Pioneer Valley while nurturing an enduring love of the land. The CEO of the company is Frank G. Haluska. | - |
Nicolas Mosimann | M | - | - | |
Joao Neves | M | - | - | |
Nuala Brennan | F | 55 | 3 years | |
Rohit Duggal | M | - |
ONK Therapeutics Ltd.
ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | - |
Dragos Budinschi | M | - | - | |
Caleb Tripp | M | 38 |
Cormorant Asset Management LLC/Private Equity/
Cormorant Asset Management LLC/Private Equity/ Investment ManagersFinance Cormorant Asset Management LLC/Private Equity/ (Cormorant Asset Management) is a venture capital subsidiary of Cormorant Asset Management LP founded in 2013 by Bi Hua Chen. The firm is headquartered in Boston, Massachusetts. | 3 years |
William Kennard | M | 67 |
Yale University
| 10 years |
William Barker | M | 75 |
The University of Colorado
| 16 years |
Laura Tadvalkar | F | - |
Expansion Therapeutics, Inc.
Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA. | 3 years |
Isaac Manke | M | 47 |
OnKure, Inc.
OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO. | 3 years |
George Schlich | M | - |
ONK Therapeutics Ltd.
ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | - |
Rahul Ballal | M | 46 | 1 years | |
Peter Feinberg | M | 63 | 3 years | |
Jaime Gerber | M | - |
Yale University
| 11 years |
Steve Blum | M | 72 |
Yale University
| 13 years |
Denis Patrick | M | - |
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Kestrel Therapeutics, Inc. is a company that has two habitat restoration projects aimed at helping native animals that are at risk, specifically the American Kestrel and the Eastern Spadefoot Toad. The company is based in Wayland, MA. The company's mission is to conserve and care for forests, farms, and riverways of the Pioneer Valley while nurturing an enduring love of the land. The CEO of the company is Frank G. Haluska. | - |
M. Isabel Chiu | M | - | 8 years | |
John DeMattei | M | - |
OnKure, Inc.
OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO. | - |
Helen Collins | M | 62 | 1 years | |
Guobao Zhao | M | - |
OnKure, Inc.
OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO. | 7 years |
Stewart Fisher | M | 57 | 8 years | |
Galya Blachman | M | 47 | - | |
Omar Khalil | M | - |
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Kestrel Therapeutics, Inc. is a company that has two habitat restoration projects aimed at helping native animals that are at risk, specifically the American Kestrel and the Eastern Spadefoot Toad. The company is based in Wayland, MA. The company's mission is to conserve and care for forests, farms, and riverways of the Pioneer Valley while nurturing an enduring love of the land. The CEO of the company is Frank G. Haluska. | 2 years |
Issac Manke | M | - |
ONK Therapeutics Ltd.
ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | - |
Patrícia Isabel Sousa Caldinha | F | - | 2 years | |
Eunan Maguire | M | - |
ONK Therapeutics Ltd.
ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | - |
Beth Seidenberg | M | 67 |
Expansion Therapeutics, Inc.
Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA. | 6 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jason S. Fisherman | M | 67 | - | |
Biren Amin | M | 51 | 1 years | |
William McKee | M | 62 | 1 years | |
Jerry Rutledge | M | 80 |
The University of Colorado
| 13 years |
Misha Levental | M | - |
The University of Colorado
| 5 years |
Goldstein Jonathan | M | - |
The University of Colorado
| 2 years |
Walead Khalid Al-Rebdi | M | - |
The University of Colorado
| 3 years |
Michael Puempel | M | - |
Yale University
| 5 years |
Jay Scollins | M | 49 |
Cormorant Asset Management LLC/Private Equity/
Cormorant Asset Management LLC/Private Equity/ Investment ManagersFinance Cormorant Asset Management LLC/Private Equity/ (Cormorant Asset Management) is a venture capital subsidiary of Cormorant Asset Management LP founded in 2013 by Bi Hua Chen. The firm is headquartered in Boston, Massachusetts. | 8 years |
Christopher Kohler | M | 44 |
The University of Colorado
| 3 years |
Luky Alfirman | M | 54 |
The University of Colorado
| 5 years |
Xiao Bin Gao | M | - |
Yale University
| 4 years |
Stewart Hanlon | M | - |
The University of Colorado
| 5 years |
Cody Weber | M | - |
The University of Colorado
| 6 years |
Jessamine Fitzpatrick | F | - |
Yale University
| 3 years |
Eva Zlotnicka | F | 41 |
Yale University
| 2 years |
Jane Jeong | F | - |
Yale University
| 4 years |
Jonathan E. Iversen | M | - |
The University of Colorado
| 3 years |
Tuan Huynh | M | - |
The University of Colorado
| 8 years |
Chris Pusey | M | - |
The University of Colorado
| 6 years |
Shawn P. Hallinan | M | - |
The University of Colorado
| 4 years |
Mark Grothe | M | - |
The University of Colorado
| 6 years |
Andrew Schwab | M | 53 | - | |
Michael Gray | M | 53 | 4 years | |
Jie Chen | M | 43 |
Yale University
| 7 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 75 | 75.76% |
Switzerland | 15 | 15.15% |
Ireland | 10 | 10.10% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Andrew Phillips
- Personal Network